Can you get Mounjaro tablets in the UK?

Why there's no Mounjaro tablet to get hold of

The search for Mounjaro tablets usually comes from one of two places: someone hoping to avoid injections, or someone who's read about oral semaglutide and wondered whether tirzepatide has followed suit. The short answer is no. Tirzepatide's chemistry makes it a peptide molecule (large, fragile, and poorly absorbed through the gut wall) so Eli Lilly brought it to market as a subcutaneous injection, which delivers the medicine reliably every week. There is no oral tirzepatide licensed anywhere in the world at the time of writing, including in the UK. If you want to understand why mounjaro tablets don't exist as a licensed product, that page covers the chemistry and regulatory position in more detail. The MHRA has been clear about the risks of buying weight-management medicines from unverified sources, and anything claiming to be an oral form of tirzepatide should be treated with serious caution.

The injectable Mounjaro KwikPen is a pre-filled device designed to be straightforward to use. Many people who started out anxious about the injection find, within a week or two, that the pen barely registers. That's not a sales pitch, it's what the clinical evidence reflects, and it's a question our prescribers field most weeks.

The oral GLP-1 option that does exist in the UK

If injections genuinely aren't for you, there is now a licensed oral alternative worth knowing about. In June 2026 the MHRA approved Wegovy tablets (oral semaglutide) as the first oral GLP-1 medicine licensed for weight management in the UK. It uses a different mechanism from tirzepatide: semaglutide is a GLP-1 receptor agonist (single pathway), while tirzepatide activates both GIP and GLP-1 receptors. In a phase 3 trial, oral semaglutide produced around 13.6% average weight loss over 64 weeks versus placebo, among participants who stayed fully adherent to treatment, that figure rose to roughly 17%. It's taken once daily, first thing in the morning on an empty stomach, at least 30 minutes before food or drink. No refrigeration needed, which matters if you travel or want to keep things discreet, the pen on a Monday morning looks different to a tablet tucked in a pocket before the school run.

Oral semaglutide is a prescription-only medicine too, so it requires the same kind of clinical assessment as the injection. You can read more about how oral tirzepatide compares to oral semaglutide as the science develops, but right now Wegovy tablets are the only licensed oral route. For a broader look at tirzepatide's clinical profile, including the SURMOUNT trial results, that detail is worth reading separately.

How injection and tablet options compare on results and eligibility

The SURMOUNT-1 trial, published in the New England Journal of Medicine, reported around 20–21% average body-weight reduction at the 15mg tirzepatide dose over 72 weeks. Oral semaglutide's trial ran for 64 weeks and found 13.6% on average, a different trial design, different population, so a direct comparison has real limits. The SURMOUNT-5 head-to-head trial compared injectable tirzepatide against injectable semaglutide 2.4mg and found tirzepatide produced greater average weight loss, but oral versus injectable semaglutide is a different question again. The honest framing: tirzepatide's injection currently shows larger average losses in trials than oral semaglutide, but the right option for any individual depends on their eligibility, health history, and what they'll realistically stick to long-term.

Both medicines are licensed for adults with a BMI of 30 or above, or 27 and above with at least one weight-related condition such as high blood pressure, high cholesterol, type 2 diabetes, or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. Neither being eligible on paper nor preferring one format over the other settles the question, a prescriber has to look at the full picture. If you're comparing costs alongside options, the treatment overview sets out what private prescription treatment includes at nume.

The decision that actually needs a prescriber

Choosing between injectable tirzepatide and oral semaglutide isn't a consumer decision in the usual sense. Both are prescription-only medicines, a pharmacist or GP decides suitability after reviewing your health, not after you've read enough comparison articles. What you can do is go into that conversation informed: knowing that Mounjaro has no tablet form, that an oral licensed option now exists, that the two medicines work through overlapping but distinct pathways, and that the clinical evidence differs in magnitude.

At nume, every consultation is read by a GPhC-registered Independent Prescriber on the same day, a real clinician working through your answers, not software flagging a score. If you're weighing up the options and want to know whether you'd be suitable for treatment, Mounjaro's full prescribing profile is one place to start, and if you're curious about how the injection device works in practice, the mounjaro pads page explains the consumables and preparation steps that come with each pen. Our clinical team can answer questions that go beyond what a web page can settle. Check your eligibility when you're ready, there's no obligation until you've spoken to a prescriber.